TearClear has filed a notice of an exempt offering of securities to raise $15,961,748.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, TearClear is raising $15,961,748.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Stuart Raetzman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About TearClear
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development. This first in class platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. TearClear is based in Boston, MA.
To learn more about TearClear, visit https://tearclear.com/
Contact:
Stuart Raetzman, Chief Executive Officer
617-454-7251
https://www.linkedin.com/in/stuart-raetzman-33a3665/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.